Davion Healthcare announced that it has entered into a share purchase agreement to acquire 100% of Humaskan, a medical technology company focused on proprietary healthcare products and intellectual property.
Davion Healthcare is a digital healthcare company developing non-invasive remote health monitoring solutions for the early identification of medical anomalies associated with serious health conditions.
The proposed acquisition of Humaskan includes the purchase of all issued share capital for total consideration of $60 million. The consideration is expected to include $10 million in cash and $50 million through the issuance of ordinary shares in Davion.
The equity consideration is expected to be issued at a reference price of $13.00 per share and would be subject to a nine-month lock-up arrangement, followed by orderly market disposal provisions.
Davion said the proposed acquisition follows its recently announced acquisition of Solar Medical and Chemical Limited, which is intended to establish the company’s principal commercial and distribution platform in the United Kingdom.
The Humaskan acquisition is part of Davion’s broader strategy to build a healthcare platform through product development, commercial infrastructure, strategic financing capability, and selective acquisitions.
Davion also announced plans to establish Davion Healthcare Finance Ltd as a wholly owned United Kingdom subsidiary. The subsidiary is intended to support the company’s acquisition and expansion strategy across the United States and Europe.
Subject to market conditions, regulatory processes, final approvals, and completion of transaction documentation, Davion Healthcare Finance expects to establish a corporate bond program of up to £100 million.
The proposed bond program is expected to include three intended series: up to £30 million in Series 1, up to £30 million in Series 2, and up to £40 million in Series 3. Davion currently expects the bonds to carry an indicative fixed coupon of 10.5% per year and an intended five-year maturity profile.
Davion said the bonds are expected to be offered exclusively to professional, sophisticated, and institutional investors and will not be made available to retail investors.
Subject to final approvals and market conditions, Davion expects each bond series to apply for admission to trading on the Vienna Stock Exchange MTF platform. The company currently anticipates launch activities beginning in August 2026.
Proceeds raised under the proposed program are expected to support Davion’s acquisition program across the United States and Europe. The company said the structure is intended to provide additional funding flexibility for disciplined capital deployment.
Completion of the Humaskan acquisition and implementation of the financing program remain subject to definitive documentation, regulatory considerations, and customary closing conditions.
KEY QUOTES:
“The proposed acquisition of Humaskan and the intended establishment of Davion Healthcare Finance Ltd reflect our strategy of building a broader and more scalable healthcare platform.”
“We believe combining proprietary technologies, commercial capability, targeted acquisitions and access to long-term institutional capital has the potential to create a flexible foundation for future growth.”
“Our intention is to create a financing platform capable of supporting disciplined acquisition activity whilst maintaining a long-term approach to value creation.”
Jack Kaye, CEO of Davion Healthcare
